Serum and macular response to carotenoid-enriched egg supplementation in human subjects: the Egg Xanthophyll Intervention clinical Trial (EXIT)

David Kelly1*, John M. Nolan1, Alan N. Howard2,3, Jim Stack1, Kwadwo O. Akuffo1, Rachel Moran1, David I. Thurnham4, Jessica Dennison1, Katherine A. Meagher1 and Stephen Beatty1

1Macular Pigment Research Group, Nutrition Research Centre Ireland, School of Health Sciences, Waterford Institute of Technology, Waterford X91 K236, Republic of Ireland
2Howard Foundation, Cambridge CB25 ONW, UK
3Downing College, University of Cambridge, Cambridge CB2 1DQ, UK
4Northern Ireland Centre for Food and Health (NICHE), University of Ulster, Coleraine BT52 1SA, UK

(Submitted 5 July 2016 – Final revision received 30 September 2016 – Accepted 11 October 2016)

Abstract
The macular carotenoids lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) accumulate at the macula, where they are collectively referred to as macular pigment (MP). Augmentation of this pigment, typically achieved through diet and supplementation, enhances visual function and protects against progression of age-related macular degeneration. However, it is known that eggs are a rich dietary source of L and Z, in a highly bioavailable matrix. In this single-blind placebo-controlled study, L- and MZ-enriched eggs and control non-enriched eggs were fed to human subjects (mean age 41 and 35 years, respectively) over an 8-week period, and outcome measures included MP, visual function and serum concentrations of carotenoids and cholesterol. Serum carotenoid concentrations increased significantly in control and enriched egg groups, but to a significantly greater extent in the enriched egg group ($P<0.001$ for L, Z and MZ). There was no significant increase in MP in either study group post intervention, and we saw no significant improvement in visual performance in either group. Total cholesterol increased significantly in each group, but it did not exceed the upper limit of the normative range (6.5 mmol/L). Therefore, carotenoid-enriched eggs may represent an effective dietary source of L, Z and MZ, reflected in significantly raised serum concentrations of these carotenoids, and consequently improved bioavailability for capture by target tissues. However, benefits in terms of MP augmentation and/or improved visual performance were not realised over the 8-week study period, and a study of greater duration will be required to address these questions.

Key words: Lutein: Zeaxanthin: Meso-zeaxanthin: Macular pigment: Carotenoid-enriched eggs: Serum carotenoids: Cholesterol

Lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) are oxygenated xanthophylls belonging to a group of plant pigments known as carotenoids(1–3). These three nutrients accumulate at the back of the human eye, in the central part of the retina (the macula, a specialised tissue that mediates central vision)(2), where they are collectively known as macular pigment (MP). MP has been shown to protect against progression of age-related macular degeneration (AMD), a disease of the macula, which is the leading cause of age-related blindness in the developed world(3–5). This protection conferred upon the macula is achieved through MP’s antioxidant properties, which enable it to quench unstable reactive oxygen species and prevent consequential damage to the retinal photoreceptors(6–9), and also through its optical light-filtering properties, which facilitate absorption of high-energy, short-wavelength damaging blue light(10,11). MP has also been shown to improve visual function(12) in both diseased(13–15) and non-diseased (healthy)(16) eyes. We know that in healthy subjects, free of retinal disease (similar to the subjects recruited into this trial), enrichment of MP following supplementation with a combination of L, Z and MZ exhibits clinically meaningful improvements in visual function(12). In addition, other in vivo murine work has shown that L has the capacity to both inhibit downstream pathological signals of oxidative stress in the retina and preserve visual function at the molecular level(16). Moreover, in similar in vivo work, L was shown to be beneficial in tight-junction repair in the retina(17), whereas human supplementation trials have indicated that MZ may positively alter the alternative complement activation pathway by lowering systemic levels of factor D, which has been found in elevated levels in the blood of AMD patients(17).

Recent studies have also confirmed the presence of L and Z in the non-human primate brain(18) and the human brain(19–21),

Abbreviations: BCVA, best-corrected visual acuity; CisZ, cis-zeaxanthin; cpd, cycles per degree; CS, contrast sensitivity; EXIT, Egg Xanthophyll Intervention clinical Trial; L, lutein; MP, macular pigment; MZ, meso-zeaxanthin; WIT, Waterford Institute of Technology; TZ, total zeaxanthin; Z, zeaxanthin.

* Corresponding author: Dr D. Kelly, email davidkelly_24@yahoo.co.uk

© The Authors 2017. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
and in concentrations that are proportional to retinal concentrations of these carotenoids. Interestingly, there is a growing body of evidence that these carotenoids may be important in maintaining optimal cognitive function\(^{28-31}\).

To date, the majority of studies investigating the role of these carotenoids for vision and cognitive function have relied on the use of commercially available supplement formulations. Recently, it has been suggested that novel nutrient-enriched (functional) foods may offer an alternative and a possibly more convenient source of nutrients to consumers, with eggs and milk being two potential candidates for L, Z and MZ\(^{32-37}\).

Daily intake of L and Z in a typical Western diet is 1–3 mg\(^{38}\), with up to 78% sourced from vegetable intake, such as spinach and kale, and maize products\(^{39,40}\). In contrast, MZ has only been identified (in trace amounts) in seafood such as trout, sardines, salmon, shrimp and turtles\(^{41,42}\). Interestingly, and in spite of the lack of dietary MZ, this xanthophyll still accounts for one-third of total MP\(^{43}\), and studies have suggested that MZ is produced by isomerisation of L in the macula\(^{44}\), but this proposed process is poorly understood\(^{45}\). Importantly, MZ has been shown to be MP’s centrally dominant constituent carotenoid\(^{46}\). In addition, it has been shown (in vitro) that MZ exhibits the greatest antioxidant activity of the three carotenoids, but the combination of all three (L, Z and MZ) exhibits an even greater antioxidant activity\(^{47}\).

The bioavailability of carotenoids in the diet is determined by the characteristics of the food matrix in which they are delivered and by possible interactions with other dietary components\(^{48}\). For example, localisation of L and Z within the chromoplasts of vegetables reduces their bioavailability to serum when ingested and, accordingly, decreasing the food particle size (by chopping, blending, pureeing, etc.) and breaking the cell wall (by cooking), before consumption, is often necessary for optimal absorption\(^{49-53}\). Of interest, studies have shown that the bioavailability of the macular carotenoids may be enhanced when dissolved in a lipid matrix, such as that of the egg yolk, which contains digestible lipids such as cholesterol, TAG and phospholipids, as this facilitates efficient digestion and absorption\(^{54}\). Interestingly, several studies have shown that the bioavailability of L and Z from eggs is superior to that from other food sources and from dietary supplement\(^{55,56}\).

This is likely because of the presence of HDL found in high concentrations in eggs, which is known to be the primary transport vehicle for L in the bloodstream\(^{57-59}\).

Hen eggs are produced on an industrial scale, and are consumed as part of a typical diet, and they provide many nutritional benefits\(^{60}\). It has been well documented that supplementation with MP’s constituent carotenoids increases both the serum and retinal concentrations of these nutrients\(^{14,61}\), and this has also been demonstrated using carotenoid-rich foods, including eggs\(^{38,62-64}\). Accordingly, considering the high HDL content of egg yolks, it is reasonable to hypothesise that consumption of carotenoid-enriched eggs could offer a unique delivery vehicle for gastrointestinal absorption and subsequent bioavailability for uptake and capture by target tissues (including retina and brain). In previous work, we supplemented the feed of Goldline hens with oil-based L, Z and MZ formulations, which resulted in the production of macular carotenoid-enriched eggs containing L and MZ in a 1:1 ratio in their yolks\(^{65}\).

In the current study, known as the Egg Xanthophyll Intervention clinical Trial (EXIT), we report on the outcomes of feeding these eggs to human subjects in terms of serum concentrations of the macular carotenoids (and cholesterol), MP and visual function.

**Methods**

**Study design and subjects**

EXIT is a single-blind placebo-controlled 8-week clinical trial that studied the impact of macular carotenoid-enriched eggs on serum carotenoid concentrations, visual performance, MP and serum cholesterol levels in human subjects. All subjects signed an informed consent document, confirming their willingness to participate in the trial. Ethical approval for the trial was granted by the Ethical Committee of the Waterford Institute of Technology (WIT), Waterford, Ireland, and the trial also conformed to the tenets of the Declaration of Helsinki. The EXIT trial was registered on the website www.controlled-trials.com (registration number ISRCTN25867083) on the 9th of August 2013 before participant enrollment. The study was then initiated in September 2013 (first subject study visit) and completed in November 2013 (last subject study visit). For a graphical summary of the paper, see the CONSORT diagram (online Supplementary material).

The main outcome measures of the trial were serum carotenoid concentrations, MP, visual function and serum cholesterol levels.

Totally, fifty subjects between the ages of 18 and 65 years were recruited into the trial from the staff of WIT, at two different sites: site 1, the Tourism and Leisure building on the main WIT campus, and site 2, the Arc Labs building at the WIT west campus. Inclusion criteria for EXIT included the following: no known allergy to eggs, no history of CVD, no ocular pathology and cholesterol levels of ≤6.5 mmol/l. In addition, subjects with current or recent history of supplementation with the macular carotenoids and/or cholesterol-lowering statins were excluded from the trial. The fifty subjects were divided equally into two groups of twenty-five.

For two-tailed tests at the 5% level of significance, a sample of this size has power of 0.97 to detect an effect size (the size of the mean difference between the two groups) of 0.8 SD (of the variable of interest) within groups (paired t-test) and a power of 0.79 to detect an effect size of 0.8 SD between groups (independent samples t-test); the sample does not have sufficient power to detect smaller effect sizes of, for example, 0.5 SD.

Group 1 was supplemented daily with a standard control (placebo) egg at site 1, on the main WIT campus, whereas group 2 was given a macular carotenoid-enriched egg (active intervention), containing L:MZ in a 1:1 ratio at site 2, on the WIT west campus. There was a 3-km distance between both study sites. Each group was based on a different campus site to avoid possible ‘contamination’ of egg samples between the two groups, and also to preserve the single-blind (masked) nature of the trial, as the macular carotenoid-enriched eggs had a more pronounced yellow colour than the control eggs, and these...
colour differences may have been discerned by participants if mixing of the two groups had been allowed. Supplementation periods were also staggered between the two groups to accommodate the completion of final visits within 1 week of ending the supplementation period, as testing all subjects in 1 week would not be logistically feasible at our research centre. As a result, participants were not randomly assigned to the two intervention groups. Vision testing was carried out on all subjects at baseline and final visits, whereas serum carotenoids and total cholesterol levels were examined at baseline, week 4 and final visit. Clinical assessments were conducted by J. D., a researcher who was suitably trained on all aspects of the EXIT protocols.

Study supplement: carotenoid-enriched hen eggs

Production of the carotenoid-enriched eggs has been described previously\(^\text{65}\). In brief, 120 Goldline hens, of approximately 20 weeks of age, were divided into two groups of sixty hens. For the duration of the trial, the hens were housed in a purpose-built barn on a farm in County Kilkenny in Southern Ireland. This barn was tested and quality assured by the Food Safety Authority of Ireland, and complied with all health standards prescribed by the Irish Food Board (BordBía), including testing for the presence of salmonella. The first group of hens was fed a standard complete grain feed, whereas the second group was given the same standard grain feed as hens in group 1, but incorporating MZ and L in a 1:1 ratio (70 mg/kg of each), for the generation of a 140 mg/kg carotenoid-enriched feed. The feed was stored sealed (at room temperature), to prevent contamination, in 60-kg containers, and fresh feed was provided daily in the barns to accommodate the completion of daily and labelled with group numbers to avoid cross-contamination between control eggs and carotenoid-enriched eggs. This was done to allow the eggs to reach their yolk carotenoid saturation point. Any eggs collected between weeks 1 and 3 of hen supplementation were hence disposed of as they were not considered suitable as subject supplementation eggs.

Eggs intended for subject supplementation were collected daily and labelled with group numbers to avoid cross-contamination between control eggs and carotenoid-enriched eggs. These eggs were then transported to site 1 and refrigerated at 5°C until they were cooked for consumption, which took place within 1 week of the egg collection. As a quality check, four eggs were sampled weekly from both trial groups and tested for yolk carotenoid concentrations, as described previously\(^\text{65}\).

With regard to the cooking of the eggs used in the EXIT trial, all eggs were prepared by one chef, and scrambling was chosen as the cooking method following the assessment of various cooking options such as boiling, frying and scrambling, as scrambling of the eggs yielded similar concentrations of carotenoids as the other cooking methods but was considered more convenient logistically. To ensure reproducibility, a two-egg scrambled portion was measured using a standardised cup for each individual subject portion. This cooking method was selected for the comparable dosage that could be achieved between subjects when the eggs were prepared in batch form, and also for logistical reasons, namely for the ease of transportation of the group 2 eggs to site 2. This was achieved in a temperature-controlled ‘hot box’, which kept the temperature of the eggs constant (<10°C drop) during transit. To account for any tedium that may be experienced because of the necessity for daily consumption of scrambled eggs for an 8-week study period, different side options were served along with the eggs. Coffee, tea and orange juice were served with breakfast each day, with toast as a side option on Mondays, Wednesdays and Fridays, croissants on Tuesdays and English muffins on Thursdays. A study investigator attended both sites for the duration of the trial to monitor compliance, and in the event that any subjects were absent two eggs were given to them to take home and prepare themselves either that day or on a weekend day to account for their day of absence on site. This ensured that 100% compliance was achieved with all subjects. Eggs were not consumed on weekend days (Saturday and Sunday) as a normal part of the trial.

Macular pigment measurement

MP was measured at baseline and at final visit (8 weeks) by both customised heterochromatic flicker photometry using the Macular Denstimeter (Macular Metrics Corp.)\(^\text{66,67}\) and by dual-wavelength autofluorescence using the Spectralis HRA+ OCT Multicolour (Heidelberg Engineering GmbH). Detailed descriptions of the techniques for MP measurement by both the Denstimeter\(^\text{68,69}\) and the Spectralis\(^\text{70,71}\) have been previously reported\(^\text{26}\). For the purposes of the current clinical trial, MP at 0·25, 0·5 and 1·0° of retinal eccentricity (Densitometer) and MP at 0·23, 0·51 and 1·02°, in addition to total MP volume (Spectralis), all with a reference point at 7°, are reported.

Visual function assessment

Visual function of the EXIT subjects was assessed by contrast sensitivity (CS) and best-corrected visual acuity (BCVA). BCVA was measured with a computerised Early Treatment Diabetic Retinopathy Study (ETDRS) logarithm of the minimum angle of resolution (LogMAR) test chart (Test Chart 2000 Xpert; Thomson Software Solutions) at a distance of 4 m. Letter CS was assessed using the computerised LogMAR ETDRS test chart (Test Chart 2000 PRO; Thomson Software Solutions) at five different spatial frequencies (1·2, 2·4, 6·0, 9·6, 15·15 cycles per degree (cpd)). In addition, CS was assessed using the Functional Vision Analyzer (Stereo Optical Co. Inc.)\(^\text{72}\), which uses the functional acuity contrast test (FACT) at five different spatial frequencies (1·5, 3, 6, 12, 18 cpd) and under the following light conditions: mesopic, photopic, mesopic with glare and photopic with glare. Detailed descriptions of these visual function techniques have been previously described\(^\text{73}\).

Serum carotenoid analysis

Serum L and total zeaxanthin (TZ) (including Z, MZ and cis-zeaxanthin (CisZ)) concentrations were measured at baseline, trial midpoint (4 weeks) and at the final subject
visit (8 weeks). Non-fasting blood samples were collected from study subjects at each visit, as previously described[280], and stored at −80°C until the time of analysis. Serum carotenoid measurements were determined using two separate HPLC assays: assay 1, a reversed-phase HPLC assay, which quantified both L and TZ concentrations, as previously described[741], and assay 2, a normal-phase assay, which exploited chiral chromatography to separate the Z and MZ enantiomers that were collected as a TZ peak in assay 1. A detailed description of HPLC assay 2 has also been described previously[41].

Egg yolk carotenoid analysis

Four eggs were removed each week from group 1 and group 2 egg batches and analysed for their carotenoid content. This was performed to investigate whether carotenoid levels remained constant in the supplemental eggs over the course of the trial. Preparation of the egg yolks, extraction of the carotenoids and their analysis by HPLC were performed as previously described[65].

Serum cholesterol analysis

Total cholesterol. Total cholesterol was measured using the handheld Roche Accutrend Plus instrument (Accutrend Cholesterol Cobas® system, list number 11418262, 2014; Roche Diagnostics GmbH) and associated Roche cholesterol test strips (DocCheck; Amtsgericht Stuttgart), by the classical finger prick method at baseline, trial midpoint (beginning of week 5) and at the final subject visit (8 weeks). Cholesterol levels were monitored in the EXIT trial to ensure that no subjects’ cholesterol level became elevated >6.5 mmol/l.

Serum HDL-cholesterol. HDL levels of non-fasting serum samples collected at the EXIT subjects study visits were measured by Claymon Laboratories Ltd (Biomnis Ireland). HDL-cholesterol was measured using the Abbott Architect Ultra N-geneous® HDL assay (HDL-cholesterol: Abbott Architect Ultra HDL Instructions for Use, list number 3K33-21, August 2015; Abbott Laboratories).

Serum LDL-cholesterol. LDL levels of non-fasting serum samples collected at the EXIT subjects’ study visits were measured by Claymon Laboratories Ltd (Biomnis Ireland). LDL-cholesterol was measured using the MULTIGENT Direct LDL assay (LDL-cholesterol: Abbott Architect Direct LDL Instructions for Use, list number 1E31-20, August 2015; Abbott Laboratories).

Serum TAG. Serum TAG levels of non-fasting serum samples collected at the EXIT subjects’ study visits were measured by Claymon Laboratories Ltd (Biomnis Ireland). Serum TAG were measured using the Abbott Architect Triglyceride assay (Triglycerides: Abbott Architect Triglycerides reagent kit instructions for use, list number 7D74, December 2012; Abbott Laboratories).

Statistical analysis

The statistical package IBM SPSS version 21 was used for all statistical analyses. Between-group differences (between control and carotenoid-enriched egg groups) at baseline were investigated using independent-sample t or χ² tests as appropriate, and any variables (such as age or sex) found to be significantly different between the two groups were controlled for in subsequent analyses. Changes over time in the primary and secondary outcome measures were analysed using both paired t tests (for within-group changes over time) and general linear models, the latter controlling for variables found to be significantly different between groups at baseline. The 5% significance level was used throughout all analyses, without any adjustment for multiple tests.

Results

Subject dropouts and adverse events

Of the fifty subjects originally enrolled in the study, two were removed from the study at midpoint (4 weeks), as their measured cholesterol concentrations exceeded the predetermined upper threshold limit of 6.5 mmol/l. Two further subjects also withdrew from the trial for personal reasons. Therefore, forty-six subjects (twenty-three in each study group) successfully completed the trial. There were no adverse events reported by subjects in either study group over the course of the trial.

Baseline differences between the two study groups

Table 1 presents the baseline demographic, health and lifestyle, MP, cholesterol and serum carotenoid data of the control egg group and carotenoid-enriched egg group subjects in the EXIT clinical trial. As presented in Table 1, the variables for which we found statistically significant differences between the study groups were age, sex and TAG levels, and hence we controlled for these in subsequent analyses, where appropriate.

Within-group changes over time (paired-sample t tests)

The first research question addressed was as follows: which study variables changed significantly over the 8-week study period? Table 2 displays, separately for the intervention and control groups, the results of paired t test analyses for all MP, serum, cholesterol and vision variables. Statistically significant differences in the table are indicated using asterisk.

Between-group changes over time (repeated measures)

The second research question addressed was as follows: which study variables changed significantly more in the enriched egg group compared with the control group? Repeated-measures ANOVA was used in this part of the study, to compare change in these variables between intervention and control groups. These analyses controlled for baseline age, TAG (except when the outcome variable was cholesterol related) and sex, all of which were significantly different between intervention and control groups at baseline. Results from analyses, within-group
Table 1. Baseline demographic, health and lifestyle, cholesterol, macular pigment (MP), visual function and serum carotenoid data of the control group and enriched-group subjects (Mean values and standard deviations for numerical data and percentages for categorical data)

| Variables | Control group (n = 25) | Enriched-group (n = 25) | Sig. |
|-----------|------------------------|------------------------|------|
| Age (years) | 41 (10) | 35 (8) | 0.015* |
| BMI (kg/m²) | 25 (3.6) | 25.7 (3) | 0.478 |
| Diet score (estimated L and Z intake) | 20.5 (14.6) | 21.5 (9.6) | 0.776 |
| Exercise (minimum (h/week)) | 329-4 (322-6) | 219-8 (136-1) | 0.124 |
| Smoking (%) | 0.583 |
| Never smoked | 64 | 68 |
| Past smoker | 16 | 20 |
| Current smoker | 20 | 12 |
| Education (highest level %) | 0.412 |
| Primary | 4 | 0 |
| Secondary | 4 | 4 |
| Higher (third level) | 92 | 96 | 0.001* |
| Sex (%) | | | |
| Male | 40 | 84 |
| Female | 60 | | 0.058 |
| Baseline cholesterol (mmol/l) | | | |
| HDL-cholesterol | 1.3 (0.2) | 1.1 (0.3) | 0.119 |
| LDL-cholesterol | 2.6 (0.6) | 2.6 (0.5) | 0.655 |
| Total cholesterol | 4.8 (0.5) | 4.8 (0.5) | 0.985 |
| TAG | 1.1 (0.4) | 1.6 (0.9) | 0.018* |
| Baseline MP Densitometer | | | |
| MP 0-25° | 0.527 (0.17) | 0.549 (0.19) | 0.674 |
| MP 0.5° | 0.413 (0.16) | 0.440 (0.19) | 0.596 |
| MP 1° | 0.283 (0.17) | 0.276 (0.14) | 0.895 |
| Spectralis | | | |
| MP 0-25° | 0.475 (0.13) | 0.521 (0.18) | 0.319 |
| MP 0.5° | 0.378 (0.11) | 0.414 (0.16) | 0.369 |
| MP 1° | 0.271 (0.08) | 0.272 (0.13) | 0.981 |
| MP volume | 5042 | 2054 | 5070 | 2145 | 0.962 |
| BCVA | 105 | 4.5 | 106 | 5.6 | 0.579 |

Table 1. Continued

| Variables | Control group (n = 25) | Enriched-group (n = 25) | Sig. |
|-----------|------------------------|------------------------|------|
| Baseline serum carotenoids (µmol/l) | | | |
| Lutein | 0.226 (0.13) | 0.188 (0.08) | 0.234 |
| Zeaxanthin | 0.079 (0.04) | 0.074 (0.02) | 0.531 |
| cis-Zeaxanthin | 0.024 (0.01) | 0.026 (0.01) | 0.588 |
| meso-Zeaxanthin | | | |

Variables, variables analysed in the study; control group, subjects consuming normal eggs; enriched group, subjects consuming lutein and meso-zeaxanthin enriched eggs. Sig., the statistical difference (P value) between before control and enriched-group subjects assessed using either independent samples t tests or χ² depending on the variable of interest: BMI, measure of body fat based on height and weight (i.e. the body mass divided by the square of the body height); diet score, estimated dietary intake of lutein and zeaxanthin; exercise, total exercise measured as minutes per week engaged in physical or sporting activity; smoking (%), current smoker (smoked ≥100 cigarettes in lifetime and at least one in the last year), past smoker (smoked ≥100 cigarettes in lifetime and none in the past year) or non-smoker (smoked <100 cigarettes in lifetime); education (highest level %), highest level to which the subject was educated; total cholesterol, measure of HDL, LDL and TAG levels; TAG, fat molecules found in the blood; esters composed of glycerol and three fatty acids; MP 0.25°, spatial profile of MP measured at 0.25° of retinal eccentricity with a reference point at 7° (measured using the macular densitometer); MP 0.5°, spatial profile of MP measured at 0.5° of retinal eccentricity with a reference point at 7° (measured using the Macular Densitometer®); MP 0.5°, spatial profile of MP measured at 1° of retinal eccentricity with a reference point at 7° (measured using the macular densitometer); MP 0.5°, macular pigment optical density at 0.25° of retinal eccentricity (measured using the Heidelberg Spectralis® HRA+OCT MultiColour); MP 0.5°, macular pigment optical density at 0.5° of retinal eccentricity (measured using the Heidelberg Spectralis® HRA+OCT MultiColour); MP 1°, macular pigment optical density at 1° of retinal eccentricity (measured using the Heidelberg Spectralis®); MP volume, a volume of MP calculated as MP average times the AUC out to 7° eccentricity (measured using the Heidelberg Spectralis®); BCVA, best-corrected visual acuity reported as visual acuity rating; CS, contrast sensitivity reported in LogCS; cpd, cycles per degree; M FACT, functional acuity contrast test under mesopic light conditions; P FACT, functional acuity contrast test under photopic light conditions; M2 FACT, functional acuity contrast test under mesopic with glare light conditions; PG FACT, functional acuity contrast test under photopic with glare light conditions; baseline serum carotenoids, serum concentrations of lutein, zeaxanthin, cis-zeaxanthin and meso-zeaxanthin (µmol/l).

and between-group, are presented (below) for each outcome variable. Fig. 1–4 graphically illustrate the observed statistically significant between-group changes in outcome variables over the 8-week study period.

Macular pigment measurement

MP was measured at baseline and at the final study visit (8 weeks) for both subject groups. As presented in Table 2, we found no significant MP response to egg supplementation in either the control group or the enriched egg group over the 8-week study period, nor were there significant between-group differences in MP at any measured eccentricities, whether measured on the Densitometer (MP 0.25; P = 0.840; MP 0.5; P = 0.593; MP 1.0; P = 0.759) or Spectralis (MP 0.25; P = 0.706; MP 0.5; P = 0.663; MP 1.02; P = 0.345, MP volume; P = 0.979).

Contrast sensitivity and best-corrected visual acuity

CS was measured at baseline and at the final study visit (8 weeks) for both subject groups. In relation to the within-group changes over the 8-week study period, presented in
Table 2. Within-group changes over time (paired-sample t tests) data for (a) macular pigment (MP), serum carotenoids (lutein (L), total zeaxanthin (TZ), cis-zeaxanthin (CisZ), zeaxanthin (Z) and meso-zeaxanthin (MZ), cholesterol and TAG (b) contrast sensitivity (CS) and visual acuity (VA) in the control and enriched egg groups†

(Mean values and standard deviations)

| Variables and study group | Baseline visit | Final visit | Diff. | Sig. |
|---------------------------|----------------|-------------|-------|------|
|                           | Mean           | sd           | Mean   | sd   |       |       |
| **(a) MP, serum carotenoids (L, TZ, CisZ, Z and MZ), cholesterol and TAG** |                |             |       |      |       |       |
| MP 0·25                   |                |             |       |      |       |       |
| Control                   | 0·527          | 0·18         | 0·542  | 0·21 | 0·015 | 0·507 |
| Enriched                  | 0·554          | 0·20         | 0·531  | 0·23 | −0·022| 0·448 |
| MP 0·5                    |                |             |       |      |       |       |
| Control                   | 0·410          | 0·17         | 0·437  | 0·20 | 0·027 | 0·186 |
| Enriched                  | 0·446          | 0·20         | 0·411  | 0·21 | −0·035| 0·244 |
| MP 1·0                    |                |             |       |      |       |       |
| Control                   | 0·304          | 0·17         | 0·304  | 0·15 | 0·000 | 0·980 |
| Enriched                  | 0·283          | 0·15         | 0·228  | 0·19 | −0·054| 0·158 |
| MP 0·23                   |                |             |       |      |       |       |
| Control                   | 0·470          | 0·13         | 0·485  | 0·15 | 0·015 | 0·250 |
| Enriched                  | 0·528          | 0·19         | 0·759  | 1·16 | 0·230 | 0·333 |
| MP 0·51                   |                |             |       |      |       |       |
| Control                   | 0·378          | 0·12         | 0·390  | 0·13 | 0·012 | 0·279 |
| Enriched                  | 0·421          | 0·17         | 0·421  | 0·17 | 0·000 | 0·921 |
| MP 1·02                   |                |             |       |      |       |       |
| Control                   | 0·277          | 0·09         | 0·283  | 0·09 | 0·006 | 0·163 |
| Enriched                  | 0·280          | 0·14         | 0·279  | 0·14 | 0·001 | 0·589 |
| MP volume                 |                |             |       |      |       |       |
| Control                   | 5215·91        | 2024·46      | 5276·09| 2001·63| 60·182| 0·600 |
| Enriched                  | 5216·64        | 2213·73      | 5245·55| 2253·64| 28·91 | 0·764 |
| Serum L (µmol/l)          |                |             |       |      |       |       |
| Control                   | 0·228          | 0·13         | 0·298  | 0·18 | 0·070 | <0·001*|
| Enriched                  | 0·195          | 0·08         | 0·441  | 0·15 | 0·246 | <0·001*|
| Serum TZ (µmol/l)         |                |             |       |      |       |       |
| Control                   | 0·080          | 0·04         | 0·111  | 0·05 | 0·031 | <0·001*|
| Enriched                  | 0·074          | 0·02         | 0·208  | 0·08 | 0·134 | <0·001*|
| Serum CisZ (µmol/l)       |                |             |       |      |       |       |
| Control                   | 0·025          | 0·01         | 0·048  | 0·02 | 0·203 | <0·001*|
| Enriched                  | 0·027          | 0·01         | 0·094  | 0·03 | 0·067 | <0·001*|
| Serum Z (µmol/l)          |                |             |       |      |       |       |
| Control                   | 0·080          | 0·04         | 0·111  | 0·05 | 0·031 | <0·001*|
| Enriched                  | 0·074          | 0·02         | 0·124  | 0·05 | 0·050 | <0·001*|
| Serum MZ (µmol/l)         |                |             |       |      |       |       |
| Control                   | –              | –            | –      | –    | –     | –     |
| Enriched                  | –              | 0·084        | 0·04   | 0·084| <0·001*|
| Total cholesterol (mmol/l)|                |             |       |      |       |       |
| Control                   | 4·77           | 0·52         | 5·19   | 0·63 | 0·420 | 0·002*|
| Enriched                  | 4·76           | 0·45         | 4·981  | 0·55 | 0·220 | 0·025*|
| HDL-cholesterol (mmol/l)  |                |             |       |      |       |       |
| Control                   | 1·26           | 0·25         | 1·31   | 0·27 | 0·051 | 0·112 |
| Enriched                  | 1·14           | 0·29         | 1·09   | 0·26 | −0·054| 0·065 |
| LDL-cholesterol (mmol/l)  |                |             |       |      |       |       |
| Control                   | 2·58           | 0·54         | 2·62   | 0·63 | 0·038 | 0·664 |
| Enriched                  | 2·52           | 0·47         | 2·59   | 0·55 | 0·070 | 0·444 |
| TAG (mmol/l)              |                |             |       |      |       |       |
| Control                   | 1·11           | 0·46         | 1·19   | 0·69 | 0·083 | 0·366 |
| Enriched                  | 1·61           | 0·91         | 1·54   | 0·72 | −0·070| 0·631 |

| **(b) CS and VA**          |                |             |       |      |       |       |
| Letter CS 1·2 cpd         |                |             |       |      |       |       |
| Control                   | 2·045          | 0·11         | 1·965  | 0·12 | −0·080| 0·017*|
| Enriched                  | 1·970          | 0·13         | 2·009  | 0·11 | 0·039 | 0·334 |
| Letter CS 2·4 cpd         |                |             |       |      |       |       |
| Control                   | 1·968          | 0·14         | 1·968  | 0·13 | 0·000 | 1·000 |
| Enriched                  | 1·966          | 0·12         | 1·965  | 0·12 | 0·001 | 0·971 |
| Letter CS 6 cpd           |                |             |       |      |       |       |
| Control                   | 1·704          | 0·17         | 1·684  | 0·19 | −0·020| 0·585 |
| Enriched                  | 1·697          | 0·22         | 1·712  | 0·17 | 0·015 | 0·834 |
| Letter CS 9·6 cpd         |                |             |       |      |       |       |
| Control                   | 1·478          | 0·22         | 1·466  | 0·21 | −0·012| 0·801 |
| Enriched                  | 1·484          | 0·25         | 1·541  | 0·21 | 0·057 | 0·508 |
| Letter CS 15·15 cpd       |                |             |       |      |       |       |
| Control                   | 1·102          | 0·24         | 1·095  | 0·30 | −0·007| 0·830 |
| Enriched                  | 1·182          | 0·25         | 1·140  | 0·23 | −0·042| 0·703 |
| M FACT CS 1·5 cpd         |                |             |       |      |       |       |
| Control                   | 1·754          | 0·17         | 1·740  | 0·17 | −0·013| 0·745 |
| Enriched                  | 1·789          | 0·15         | 1·743  | 0·17 | −0·046| 0·189 |
Table 2. Continued

| Variables and study group | Baseline visit | Final visit | Diff.  | Sig.  |
|---------------------------|---------------|-------------|--------|------|
|                           | Mean          | SD          | Mean   | SD   |
| **M FACT CS 3 cpd**       |               |             |        |      |
| Control                   | 1.879         | 0.22        | 1.939  | 0.15 |
| Enriched                  | 1.878         | 0.13        | 1.832  | 0.28 |
| **M FACT CS 6 cpd**       |               |             |        |      |
| Control                   | 1.654         | 0.26        | 1.691  | 0.24 |
| Enriched                  | 1.647         | 0.30        | 1.658  | 0.29 |
| **M FACT CS 12 cpd**      |               |             |        |      |
| Control                   | 1.138         | 0.36        | 1.144  | 0.36 |
| Enriched                  | 1.238         | 0.36        | 1.163  | 0.32 |
| **M FACT CS 18 cpd**      |               |             |        |      |
| Control                   | 0.548         | 0.33        | 0.520  | 0.29 |
| Enriched                  | 0.519         | 0.29        | 0.548  | 0.31 |

*Data displayed are the results of paired t-tests; CS, contrast sensitivity reported in LogCS; cpd, cycles per degree; M FACT, functional acuity contrast test under mesopic light conditions; P FACT, functional acuity contrast test under photopic light conditions; MG FACT, functional acuity contrast test under mesopic with glare light conditions; PG FACT, functional acuity contrast test under photopic with glare light conditions; BCVA, best-corrected VA reported as visual acuity rating.

†Statistically significant differences between baseline and final study visits.
††Data displayed are the results of paired t-test analyses.
Table 2, we noted a significant decrease in the control group for letter CS at 1-2 cpd (P=0.017) and a significant increase in FACT CS at 12 cpd under photopic conditions with glare (P=0.016). In the enriched egg group, there was a significant decrease in FACT CS at 12 cpd under mesopic conditions (P=0.025), and a significant increase in FACT CS at 1-5 cpd under mesopic conditions with glare (P=0.047).

Controlling for age, sex and TAG using the general linear model repeated measures test, we noted only one between-group difference over the course of the study for measures of visual function, as presented in Fig. 1. This was for the letter CS at 15-15 cpd (P=0.046), which exhibited an improvement in the enriched egg group.

BCVA was measured at baseline and at the final study visit (8 weeks) for both subject groups. As presented in Table 2, there was no significant change in BCVA in either the control (P=0.761) or enriched (P=0.074) egg groups over the course of the study. However, we did note a statistically significant between-group difference (P=0.035) after controlling for age, sex and TAG using the general linear model repeated-measures test, because of a small improvement in BCVA in the enriched egg group and a small decrease in the control group (see Fig. 2).

Serum carotenoid analysis

Serum carotenoid concentrations were measured at baseline, trial midpoint (4 weeks) and at the final subject visit (8 weeks). As presented in Table 2, serum L, TZ, Z and CisZ concentrations increased significantly over time in both the control (P=0.007, 0.009, 0.009 and <0.001, respectively) and enriched (P<0.001 for all) egg groups, whereas serum MZ concentration increased significantly only in the enriched egg group (P<0.001). In terms of between-group differences, controlling for age, sex and TAG using the general linear model repeated measures test, the enriched egg group showed a significantly greater serum response to L, TZ, CisZ and MZ (P<0.001 for all) than the control group. Both study groups were found to respond comparably with respect to Z, with no significant between-group difference noted after 8 weeks (P=0.477) (see Fig. 3).

Egg yolk carotenoid analysis

Four eggs were taken weekly from the batch of study eggs of both normal and enriched egg groups and tested for their carotenoid content for the duration of the EXIT study. These results are presented in Fig. 4. Week-to-week variation in yolk L concentrations was not statistically significant over the course of the trial in either the control (P=0.258) or enriched (P=0.126) egg groups (P values quoted are from ANOVA). However, there was significant week-to-week variation in yolk Z (P=0.052), CisZ (P=0.010) and MZ (P=0.005) concentrations in the enriched egg group.
Serum cholesterol analysis

Total cholesterol, HDL-cholesterol and TAG levels were measured at baseline, midpoint (4 weeks) and final study visit (8 weeks) for both subject groups. As presented in Table 2, total cholesterol levels increased significantly within both the control ($P=0.003$) and enriched ($P=0.025$) egg groups over the course of the study. However, we saw no statistically significant between-group differences for total cholesterol ($P=0.561$). Similarly, as presented in Table 2, we report no significant
increase ($P > 0.05$ for all), either within treatment groups or between treatment groups, in terms of HDL-cholesterol, LDL-cholesterol or TAG levels over the course of the trial.

**Discussion**

This study presents findings of the EXIT, a clinical trial designed to study the impact of the consumption of normal (control) eggs, and carotenoid (L and MZ)-enriched eggs on serum carotenoid concentrations, visual performance and MP densities in human subjects. As a secondary outcome measure, serum cholesterol levels were also monitored in both study groups over the course of the trial. The rationale and motivation for undertaking the current study relates to the suggested role that the yolk matrix, which is liquid in nature and of high lipoprotein content, may play in enhancing carotenoid absorption and, therefore, bioavailability of these compounds in humans.$^{(48,54)}$

Indeed, the potential of eggs to enhance carotenoid serum responses, when compared with other foods and supplements, has been suggested by the findings of previous studies.$^{(58,55,56)}$

It is worth noting that previous studies have investigated the consumption of both L.$^{(48,54,55,59,65,75)}$ and Z.$^{(62,76)}$-enriched eggs and their effect on MP, vision and serum concentrations of the carotenoids. In addition, there was also one study that investigated the serum response to MZ-enriched eggs$^{(38)}$.

However, the current investigation is the first to report on the serum, MP and visual response to eggs enriched with L and MZ.

The main finding from this study was that there was a statistically significant increase in serum carotenoid concentrations in the control and enriched egg groups over the course of the trial, whereas no significant MP changes were seen in either study group. In relation to visual performance, although we noted some significant trends for both CS and VA measurements (in terms of some significant, but not clinically meaningful, improvements in the enriched egg group), overall, consumption of both the control and enriched eggs over the study period appeared to show no significant effects on subject’s visual performance. A significant increase in total cholesterol was noted in both control and enriched egg groups over the course of the trial; however, no significant changes in serum HDL and LDL or TAG levels were evident.

In relation to serum carotenoid changes in this study, it was perhaps not surprising that we saw a response in both the control and enriched egg study groups, as hen eggs are known to be naturally bioavailable sources of both L and Z because of the colocalisation of these xanthophylls with egg yolk HDL.$^{(59,60,75)}$. The enriched eggs used in this study induced a response in terms of serum L concentrations that was
significantly greater than that seen among subjects supplemented with normal control eggs (increases of 126 and 31%, respectively). The serum Z response was also greater (but not significantly so) in the enriched egg group when compared with the control group (68 and 39% increases, respectively). These results are comparable with most(48,54,63,75–78), but not all(62,79,80), previous reports (Table 3). The finding by Wenzel et al.1621 that serum Z, but not serum L, increased following 12 weeks’ supplementation could perhaps be considered unusual, as most studies (including the current one) demonstrate a clear increase in serum L concentrations following egg intervention. It is perhaps worth noting, however, that a more significant increase in serum Z was indeed noted in many studies when compared with that of serum L168,54,63,75,76.

A possible contributory factor may be the effect of cooking of the eggs, as cooking-mediated losses of L have been reported to be greater than those of Z(81). Thurnham182 has reported that observed increases in plasma Z concentrations can be a function of lower baseline Z concentrations in comparison with baseline L concentrations, thereby favouring more marked rises in serum concentrations of Z.

As MZ is not present in non-enriched eggs, and no other studies investigating the consumption of MZ-enriched eggs have been published, it is difficult to discuss the between-intervention-group response to MZ in our study. However, the serum MZ response from the enriched eggs (0·118 µmol/l per mg) in the current study is comparable with that achieved in oil-based supplementation using commercially available formulations (0·004 and 0·005 µmol/l per mg, respectively)1,82, but with a considerably lower dosage (0·718 mg, as opposed to 10 and 10 mg, respectively), and is also greater than the response (0·026 µmol/l per mg) reported by Thurnham et al.183, achieved using an 8-mg supplement. Interestingly, in our study, in the enriched egg group, observed rises in serum concentrations of cisZ (which is likely to be a combination of cis-Z and cis-MZ) were similar to the observed rises in serum MZ (Fig. 3), despite the considerably higher concentrations of MZ compared with cisZ in the raw control egg yolks (Fig. 4). There may be several reasons for this observation, including the following: (1) a portion of yolk MZ (and also possibly yolk Z) may be metabolised to its respective cis form during uptake or absorption, hence contributing to the overall cisZ response – indeed, previous reports have noted augmentation of serum cisZ in response to supplementation with Z84,85; (2) there may have been thermally induced isomerisation of trans-Z and MZ during the cooking of the eggs, as this has been previously reported in the case of some vegetables, including maize186.

With respect to the relationship between serum concentrations arising from egg consumption and MP in our study, we found no significant correlations in either study group over the 8-week intervention period. This finding is in agreement with one previous report76, but in contrast to that of others62–64 (Table 3). When discussing the MP findings in the current study, it is perhaps worthwhile to note the study of Broekmans et al.187. Interestingly, in that study, in which cross-sectional data were analysed, the authors found that in a group of 376 subjects (which were almost equally split as regards sex), MP levels were 13% higher in men than in women. In contrast, serum carotenoid concentrations and adipose tissue concentrations of L were significantly higher in women (however, it is known that there is a higher concentration of adipose tissue in the body composition of women than in men188, and therefore this may naturally have influenced greater L absorption by adipose tissue in women). The observation that men exhibited lower concentrations of L in serum and in adipose tissue, and yet higher MP, suggests that men would likely be more responsive to attempts to augment MP through dietary modification, and that adipose tissue appears to compete for L with MP’s constituent carotenoids, as suggested previously189. Hence, it may be important to consider adiposity when reporting the relationship between carotenoid intake and MP.

In relation to the current study, the sex split was 84% male and 16% female in the enriched egg group, and 40% male and 60% female in the control egg group. The fact that we did not see a change in MP in the enriched egg group in the current study is perhaps unusual, given the predominance of males in that group. In this regard, it may also be important to highlight that concentrations of carotenoids in serum reflect more recent dietary intake, whereas adipose tissue concentrations more accurately reflect longer-term dietary intake of carotenoids189, and therefore in a shorter study (such as the current one) serum and adipose tissue effects on MP density may not have been elicited.

With regard to visual performance, in our study, the small number of statistically significant results for letter CS (i.e. one’s ability to discriminate the foreground from the background) and VA (i.e. sharpness of vision at 100% contrast), which we noted in the enriched egg group, should be assessed with caution. First, none of the improvements were clinically significant and, second, the statistical significance that we report (e.g. for four CS measures in Table 2) may well be a consequence of multiple testing.

An improvement in CS without an increase in MP has been noted in a previous study by our group20, although this was evident at 6 months post intervention. Overall, the lack of improvement in visual performance of the EXIT subjects is consistent with the lack of MP augmentation also observed, as it has been shown that CS improvements are typically commensurate with observed augmentations in MP20. It is also important to note that, as seen in Table 1, the baseline values for BCVA and CS in both subject groups in our study were considered high, and therefore our finding (of limited clinically meaningful improvements in their visual performance) is not unexpected, particularly considering the relatively short duration of the trial. Indeed, we have previously shown that improvements in visual performance in healthy subjects without AMD are possible over a longer duration (12 months)21. In addition, in the current study, we considered whether low and high carotenoid responders may have behaved differently in terms of their visual parameters. However, this would have reduced group sizes significantly, and after a cursory examination we felt that such an analysis would be unjustified.

We showed that total cholesterol levels increased significantly over the 8-week trial period in both the control egg (9% increase) and enriched egg (5% increase) groups, but upper limits of the normative reference values (6·5 mmol/l)
| Study                          | Year | n  | Sex | Age (years) | Study duration | Intervention                                                                 | L response | Z response | MP response |
|-------------------------------|------|----|-----|-------------|----------------|------------------------------------------------------------------------------|------------|------------|-------------|
| Handelman et al. (48)         | 1999 | 11 | 6m, 5f | 46–78     | 4-5 weeks/diet  | G1: maize oil G2: beef tallow G3: maize oil + 1.3 egg yolks daily G4: beef tallow + 1.3 egg yolks daily | G1: no response | G2: no response | G1: no response |
|                               |      |    |      |            |                | G1: no response G2: no response G3: 50% increase relative to G1 G4: 28% increase relative to G2 | G3: 114% increase relative to G1 | G4: 142% increase relative to G2 | –           |
| Goodrow et al. (54)           | 2006 | 33 | 7m, 26f | 60–96     | 8 weeks        | One egg daily 6 (L and Z in combination) enriched eggs weekly | 26% increase | –          | Sig. increase in both treatment groups, in a linear manner from 4 to 8 weeks, to 12 weeks |
| Wenzel et al. (82)            | 2006 | 24 | 0m, 24f | 24–59     | 12 weeks       | G1: 331 µg combination G2: 946 µg combination G1: 2 egg yolks daily G2: 4 egg yolks daily | G1: 50% increase | G2: 82% increase | G1: 24% increase |
| Vishwanathan et al. (83)      | 2009 | 52 | 21m, 31f | ≥ 60      | 5 weeks/phase  | G1: egg-yolk-free buttermilk drink daily G2: 1.5 egg yolk buttermilk drink enriched with L, Z and DHA daily | G1: no sig response | G2: 94% increase | G1: no sig response |
|                               |      |    |      |            |                | G1: no sig response G2: similar increase to L | G1: no sig response | G2: no sig response | G1: no sig response |
| van der Made et al. (84)      | 2016 | 100 | 32m, 68f | 62–63     | 1 year         | G1: egg-yolk-free substitute daily G2: 3 whole eggs daily G2: 1 normal egg daily G2: 1 L-enriched egg daily G2: 1 Z-enriched egg daily G2: 1 L-enriched egg yolk beverage daily | G1: no sig response | G2: 48% increase | G1: no sig response |
|                               |      |    |      |            |                | G2: 21% increase G2: no sig response G3: 76% increase G4: no sig response G5: 77% increase | G2: 48% increase | G2: no sig response | G2: no sig response |
| Kelly et al. (76)             | 2014 | 100 | 43m, 57f | ≥ 18      | 90 d           | G1: egg-yolk-free buttermilk beverage daily G2: 3 liquid eggs daily G1: unmodified diet G2: 1 normal egg daily G3: 1 L-enriched egg daily G4: 1 Z-enriched egg daily G5: 1 L-enriched egg yolk beverage daily | G1: no sig response | G2: 80% increase | G1: no sig response |
|                               |      |    |      |            |                | G2: 80% increase G2: no sig response G3: 76% increase G4: no sig response G5: 77% increase | G2: 80% increase | G2: no sig response | G2: no sig response |
| Mutungi et al. (77)           | 2010 | 31 | 31m, 0f | 40–70     | 12 weeks       | G1: egg-yolk-free substitute daily G2: 3 liquid eggs daily G1: unmodified diet G2: 1 normal egg daily G3: 1 L-enriched egg daily G4: 1 Z-enriched egg daily G5: 1 L-enriched egg yolk beverage daily | G1: – | G1: 40% decrease | – |
|                               |      |    |      |            |                | G1: no sig response G2: 80% increase G2: no sig response G3: 76% increase G4: no sig response G5: no sig response | G2: 83% increase relative to G1 | G2: 110% increase relative to G1 | – |
| van der Made et al. (78)      | 2014 | 89 | 29m, 60f | ≥ 50      | 1 year         | G1: egg-yolk-free buttermilk beverage daily G2: 3 liquid eggs daily G1: unmodified diet G2: 1 normal egg daily G3: 1 L-enriched egg daily G4: 1 Z-enriched egg daily G5: 1 L-enriched egg yolk beverage daily | G1: no sig response | G2: 80% increase | G1: no sig response |
|                               |      |    |      |            |                | G2: 83% increase relative to G1 | G2: 83% increase relative to G1 | G2: 110% increase relative to G1 | – |
| Surai et al. (79)             | 2000 | 44 | 24m, 20f | 26–59     | 8 weeks        | G1: 1 normal egg daily G2: 1 L-enriched egg daily | G1: no sig response | G2: 1.88-fold increase relative to G1 | G1: no sig response |
|                               |      |    |      |            |                | G2: 1.88-fold increase relative to G1 | G2: no sig response | G2: no sig response | – |
were not exceeded, and this finding is consistent with previous studies, where total cholesterol increases of 4\%\(^{(390)}\) and 5\%\(^{(91)}\) were reported. Moreover, we found no significant increases in LDL, HDL or TAG levels in either study group, consistent with other egg-based studies\(^{(54,62,80)}\).

The limitations of this study include the relatively short study period and small sample size, the lack of randomisation of the treatment groups and the high male:female ratio in the enriched egg group. In a follow-up clinical trial, males and females would be randomly allocated to the two treatment groups, and food colouring could also be added to both trial supplements to eliminate the need for different locations for both arms of the trial. Of note, previous work has shown that females responded better to carotenoid supplementation than males\(^{(83)}\). In addition, it has been reported that carotenoids in an egg matrix may possibly have significantly lower bioaccessibility, because of reduced retention and transfer of the carotenoids to the micelles (micellarisation), when cooked by scrambling (the method chosen in the current study) in comparison with boiling\(^{(92)}\).

In conclusion, we have shown that consumption of both normal and L- and MZ-enriched eggs significantly increased serum concentrations of MP’s constituent carotenoids after 8 weeks’ supplementation. Although measures of MP and the majority of measures of visual performance did not improve significantly in either study group, and given the observed significant increases in serum concentrations of MP’s constituent carotenoids, we feel that a study of greater duration is required before definitive conclusions can be drawn on the potential of carotenoid-enriched eggs to augment MP and/or impact favourably on vision. The finding that CisZ appeared to have greater bioaccessibility to serum than transZ and MZ is potentially interesting, and warrants further investigation. In summary, carotenoid-enriched eggs could represent a cost-effective and readily bioaccessible source of the macular carotenoids as an alternative to over-the-counter formulations.

**Supplementary material**

For supplementary material/s referred to in this article, please visit https://doi.org/10.1017/S0007114516003895.

**Acknowledgements**

The authors acknowledge the hen farmers (Kevin McKenna and Colette McKenna) who supported the original supplementation of the hen’s diets and subsequent egg collection on their farm, and we also thank Industrial Orgánica (S.A. de C.V Ave. Almazán No. 100, Col. Topo Chico, Monterrey, N.L. 64260, Mexico) for providing the carotenoid material for the trial. The authors also thank Professor Elizabeth Johnson from Tufts University, USA, for use of the ‘L/Z screener’ for the estimation of dietary intake of lutein and zeaxanthin in this study.

The EXIT clinical trial was supported by the Howard Foundation (English Charity reg. no. 285822), Cambridge, UK. D. K., K. O. A. and J. M. N. are funded by the European Research Council Starter grant (ref. 281096).

D. K. carried out database analysis and interpretation, statistical analysis and drafted the manuscript. J. M. N. and A. N. H.
References

1. Meagher KA, Thurnham DI, Beatty S, et al. (2012) Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. Br J Nutr 110, 289–300.

2. Hirsch J & Curcio CA (1989) The spatial resolution capacity of human foveal retina. Vision Res 29, 1095–1101.

3. Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291, 1900–1901.

4. Sabour-Pickett S, Nolan JM, Loughman J, et al. (2011) A review of the evidence germane to the putative protective role of the macular carotenoids for age-related macular degeneration. Mol Nutr Food Res 10, 270–286.

5. Loane E, Kelliher C, Beatty S, et al. (2008) The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. Br J Ophthalmol 92, 1163–1168.

6. Pintea A, Socaciu C, Rugina DO, et al. (2011) Xanthophylls protect against induced oxidation in cultured human retinal pigment epithelial cells. J Food Composition Anal 26, 830–836.

7. Beatty S, Koh HH, Henson D, et al. (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45, 115–134.

8. Trevithick-Sutton CC, Foote CS, Collins M, et al. (2006) The retinal carotenoids zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence and ESR study. Mol Vis 12, 1127–1135.

9. Khachik F, Beecher GR & Goli MB (1992) Separation and identification of carotenoids of carotenoids and their oxidation products in the extracts of human plasma. Anal Chem 64, 2111–2122.

10. Junghans A, Sies H & Stahl W (2001) Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch Biochem Biophys 391, 160–164.

11. Snodderly DM, Brown PK, Delori FC, et al. (1984) The macular pigment. 1. Absorption spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci 25, 660–673.

12. Nolan JM, Loughman J, Akkali MC, et al. (2011) The impact of macular pigment augmentation on visual performance in normal subjects: COMPASS. Vision Res 51, 459–469.

13. Huang YM, Yan SF, Ma L, et al. (2013) Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition 29, 387–392.

14. Sabour-Pickett S, Beatty S, Connolly E, et al. (2014) Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration. Retina 34, 1757–1766.

15. Murray IJ, Makridaki M, van der Veen RL, et al. (2013) Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Invest Ophthalmol Vis Sci 54, 1781–1788.

16. Ma I, Yan SF, Huang YM, et al. (2012) Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology 119, 2290–2297.

17. Peng ML, Chiu HF, Chou H, et al. (2016) Influence/impact of lutein complex (marigold flower and wolfberry) on visual function with early age-related macular degeneration subjects: a randomized clinical trial. J Funct Foods 24, 122–130.

18. Liu R, Wang T, Zhang B, et al. (2015) Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration. Invest Ophthalmol Vis Sci 56, 252–258.

19. Wolf-Schnurrbusch UE, Zinkernagel MS, Munk MR, et al. (2015) Oral lutein supplementation enhances macular pigment density and contrast sensitivity but not in combination with polyunsaturated fatty acids. Invest Ophthalmol Vis Sci 56, 8069–8074.

20. Loughman J, Nolan JM, Howard AN, et al. (2012) The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci 53, 7871–7880.

21. Nolan JM, Power R, Stringham J, et al. (2016) Enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: Central Retinal Enrichment Supplementation Trials – Report 1. Invest Ophthalmol Vis Sci 57, 3420–3439.

22. Ozawa Y, Sasaki M, Takahashi N, et al. (2012) Neuroprotective effects of lutein in the retina. Curr Pharm Des 18, 51–56.

23. Kamoshita M, Toda E, Osada H, et al. (2016) Lutein acts via multiple antioxidant pathways in the photo-stressed retina. Sci Rep 6, 30226.

24. Vishwanathan R, Neuringer M, Snodderly DM, et al. (2012) Macular lutein and zeaxanthin are related to brain lutein and zeaxanthin in primates. Nutr Neurosci 16, 21–29.

25. Craft NE, Haltema TB, Garnett KM, et al. (2004) Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8, 156–162.

26. Vishwanathan R, Kuchan MJ, Sen S, et al. (2014) Lutein and preterm infants with decreased concentrations of brain carotenoids. J Pediatr Gastroenterol Nutr 59, 659–665.

27. Johnson EJ, Vishwanathan R, Johnson MA, et al. (2013) Relationship between serum and brain carotenoids, alphatocopherol, and retinol concentrations and cognitive performance in the oldest old from the Georgia Centenarian Study. J Aging Res 2013, 951786.

28. Kelly D, Coen RF, Akuffo KO, et al. (2015) Cognitive function and its relationship with macular pigment optical density and serum concentrations of its constituent carotenoids. J Alzheimers Dis 48, 261–277.

29. Vishwanathan R, Iannaccone A, Scott TM, et al. (2014) Macular pigment optical density is related to cognitive function in older people. Age Ageing 43, 271–275.

30. Renzi LM, Dengler MJ, Puente A, et al. (2014) Relationships between macular pigment optical density and cognitive function in unimpaired and mildly cognitively impaired older adults. Neurobiol Aging 35, 1695–1699.

31. Johnson EJ, Vishwanathan R & Schalch W (2011) Brain levels of lutein (L) and zeaxanthin (Z) are related to cognitive function in centenarians. FASEB J 25, 1 Suppl., 975.21.
32. Goldberg EM, Anjum FM, Nedenc M, et al. (2015) Production of bio-omega-3 eggs through the supplementation of extruded flaxseed meal in hen diet. Lipids Health Dis 14, 126.

33. Goldberg EM, Gakhar N, Ryland D, et al. (2012) Fatty acid profile and sensory characteristics of table eggs from laying hens fed flaxseed and flaxseed oil. J Food Sci 77, S153–S160.

34. Lewis NM, Seburg S & Flanagan NL (2000) Enriched eggs as a source of n-3 polyunsaturated fatty acids for humans. Poult Sci 79, 971–974.

35. Goldberg EM, Ryland D, Gibson RA, et al. (2013) Designer laying hen diets to improve egg fatty acid profile and maintain sensory quality. Food Sci Nutr 1, 324–335.

36. Stergiadis S, Leifert C, Seal CJ, et al. (2014) Improving the fatty acid profile of winter milk from housed cows with contrasting feeding regimes by oilseed supplementation. Food Chem 164, 292–300.

37. Rahmawaty S, Lyons-Wall P, Charlton K, et al. (2007) Macular zeaxanthins and lutein and zeaxanthin stereoisomers in the human retina. Br J Ophthalmol 82, 907–910.

38. Penny A, Rasmussen H & Johnson EJ (2009) Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn and egg products. J Food Composition Anal 22, 9–15.

39. Maoka T, Arai A, Shimizu M, et al. (1986) The first isolation of enantiomeric and meso-zeaxanthin in nature. Comp Biochem Physiol B 83, 121–124.

40. Nolan JM, Beatty S, Meagher KA, et al. (2014) Verification of zeaxanthin in fish. J Food Process Technol 5, 335.

41. Bone RA, Landrum JT, Henry GW, et al. (1993) Stereocomposition of the human macular carotenoids. Invest Ophthalmol Vis Sci 34, 2033–2040.

42. Johnson EJ, Neuringer M, Russell RM, et al. (2005) Nutritional manipulation of primate retinas, III: effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys. Invest Ophthalmol Vis Sci 46, 692–702.

43. Nolan JM, Meagher K, Kashani S, et al. (2013) What is meso-zeaxanthin, and where does it come from? Eye (Lond) 27, 899–905.

44. Bone RA, Landrum JT, Friedes LM, et al. (1997) Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res 64, 211–218.

45. Li B, Ahmed F & Bernstein PS (2010) Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch Biochem Biophys 504, 56–60.

46. Handelman GJ, Nightingale ZD, Lichtenstein AH, et al. (1999) Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg yolk. Am J Clin Nutr 70, 247–251.

47. Rich GT, Bailey AL, Faulks RM, et al. (2003) Solubilization of carotenoids from carrot juice and spinach in lipid phases: I. Modeling the gastric lumen. Lipids 38, 933–945.

48. Erdman JW Jr, Bierer TL & Gugger ET (1993) Absorption and transport of carotenoids. Annu N Y Acad Sci 691, 76–85.

49. Rock CL, Loyallo JD, Emenhiser C, et al. (1998) Bioavailability of beta-carotene is lower in raw than in processed carrots and spinach in women. J Nutr 128, 913–916.

50. Yeum KJ & Russell RM (2002) Carotenoid bioavailability and bioconversion. Annu Rev Nutr 22, 483–504.

51. Couarra J, Berger J, Cristol JP, et al. (2013) Stability and bioaccessibility of different forms of carotenoids and vitamin A during in vitro digestion. Food Chem 136, 871–877.

52. Goodrow EF, Wilson TA, Houde SC, et al. (2006) Consumption of one egg per day increases serum lutein and zeaxanthin concentrations in older adults without altering serum lipid and lipoprotein cholesterol concentrations. J Nutr 136, 2519–2524.

53. Chung RY, Rasmussen HM & Johnson EJ (2004) Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. J Nutr 134, 1887–1893.

54. Hammond BR, Johnson EJ, Russell RM, et al. (1997) Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci 38, 1795–1801.

55. Wang W, Connors SL, Johnson EJ, et al. (2007) Effect of dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in age-related macular degeneration. Am J Clin Nutr 85, 762–769.

56. Loane E, Nolan JM & Beatty S (2010) The respective relationships between lipoprotein profile, macular pigment optical density, and serum concentrations of lutein and zeaxanthin. Invest Ophthalmol Vis Sci 51, 5987–5995.

57. Greene CM, Waters D, Clark RM, et al. (2006) Plasma LDL and HDL characteristics and carotenoid content are positively influenced by egg consumption in an elderly population. Nutr Metab (Lond) 3, 6.

58. McNamara DJ (2015) The Fifty Year Rehabilitation of the Egg. Nutrients 7, 8716–8722.

59. Thurnham DI, Nolan JM, Howard AN, et al. (2015) Macular response to supplementation with differing xanthophyll formulations in subjects with and without age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 253, 1231–1243.

60. Wenzel AJ, Gerweck C, Barbato D, et al. (2000) A 12-wk egg intervention increases serum zeaxanthin and macular pigment optical density in women. J Nutr 130, 2568–2573.

61. Vishwanathan R, Goodrow-Kotyla EF, Wooten BR, et al. (2009) Consumption of 2 and 4 egg yolks/d for 5 wk increases macular pigment concentrations in older adults with low macular pigment intake and cholesterol-lowering statins. Am J Clin Nutr 90, 1272–1279.

62. van der Made SM, Kelly ER, Kijkstra A, et al. (2016) Increased macular pigment optical density and visual acuity following consumption of a buttermilk drink containing lutein-enriched egg yolks: a randomized, double-blind, placebo-controlled trial. J Ophthalmol 2016, 9035745.

63. Nolan JM, Meagher KA, Howard AN, et al. (2016) Lutein, zeaxanthin and meso-zeaxanthin content of eggs laid by hens supplemented with free and esterified xanthophylls. J Nutr Sci 5, e1.

64. Wooten BR & Hammond BR (2005) Spectral absorbance and spatial distribution of macular pigment using heterochromic flicker photometry. Optom Vis Sci 82, 378–386.

65. Wooten BR, Hammond BR, Land RI, et al. (1999) A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 40, 2481–2489.

66. Loane E, Stack J, Beatty S, et al. (2007) Measurement of macular pigment optical density using two different heterochromatic flicker photometers. Curr Eye Res 32, 555–564.

67. Stringham JM, Hammond BR, Nolan JM, et al. (2008) The utility of using customized heterochromatic flicker photometry (cHFP) to measure macular pigment in patients with age-related macular degeneration. Exp Eye Res 87, 445–453.
Lutein and _meso_-zeaxanthin-enriched egg trial

70. Delori FC, Goger DG, Hammond BR, et al. (2001) Macular pigment density measured by autofluorescence spectrometry: comparison with reflectometry and heterochromatic flicker photometry. *J Opt Soc Am A Opt Image Sci Vis* **18**, 1212–1230.

71. Wustemeyer H, Jahn C, Nestler A, et al. (2002) A new instrument for the quantification of macular pigment density: first results in patients with AMD and healthy subjects. *Graefes Arch Clin Exp Ophthalmol* **240**, 666–671.

72. Holberger B, Laemmer R, Adler W, et al. (2007) Measuring contrast sensitivity in normal subjects with OPTEC 6500: influence of age and glare. *Graefes Arch Clin Exp Ophthalmol* **245**, 1805–1814.

73. Akuffo KO, Beatty S, Stack J, et al. (2014) Central Retinal Enrichment Supplementation Trials (CREST): design and methodology of the CREST randomized controlled trials. *Ophthalmic Epidemiol* **21**, 111–123.

74. Nolan JM, Loskutova E, Howard AN, et al. (2014) Macular pigment, visual function, and macular disease among subjects with Alzheimer’s disease: an exploratory study. *J Alzheimers Dis* **42**, 1191–1202.

75. Blesso CN, Andersen CJ, Bolling BW, et al. (2013) Egg intake improves carotenoid status by increasing plasma HDL cholesterol in adults with metabolic syndrome. *Food Funct* **4**, 213–221.

76. Kelly ER, Plat J, Haenen GR, et al. (2014) The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial. *PLOS ONE* **9**, e92659.

77. Mutungi G, Waters D, Ratliff J, et al. (2010) Eggs distinctly modulate plasma carotenoid and lipoprotein subclasses in adult men following a carbohydrate-restricted diet. *J Nutr Biochem* **21**, 261–267.

78. van der Made SM, Kelly ER, Berendschot TT, et al. (2014) Consuming a buttermilk drink containing lutein-enriched egg yolk daily for 1 year increased plasma lutein but did not affect serum lipid or lipoprotein concentrations in adults with early signs of age-related macular degeneration. *J Nutr* **144**, 1370–1377.

79. Surai PF, MacPherson A, Speake BK, et al. (2000) Designer egg evaluation in a controlled trial. *Eur J Clin Nutr* **54**, 298–305.

80. Burger M, Quataert M, Kamps L, et al. (2014) Bioavailability of lutein from a lutein-enriched egg-yolk beverage and its dried re-suspended versions. *Int J Food Sci Nutr* **65**, 903–909.

81. Nimalaratne C, Lopes-Lutz D, Schieber A, et al. (2012) Effect of domestic cooking methods on egg yolk xanthophylls. *J Agric Food Chem* **60**, 12547–12552.

82. Connolly EE, Beatty S, Thurnham DI, et al. (2010) Augmentation of macular pigment following supplementation with all three macular carotenoids: an exploratory study. *Curr Eye Res* **35**, 335–351.

83. Thurnham DI, Tremel A & Howard AN (2008) A supplementation study in human subjects with a combination of _meso_-zeaxanthin, (3R,3'R)-zeaxanthin and (3R,3'R,6'R)-lutein. *Br J Nutr* **100**, 1307–1314.

84. Landrum JT & Bone RA (2001) Lutein, zeaxanthin, and the macular pigment. *Arch Biochem Biophys* **385**, 28–40.

85. Khachik F, Bernstein PS & Garland DL (1997) Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. *Invest Ophthalmol Vis Sci* **38**, 1802–1811.

86. Aman R, Biehl J, Carle R, et al. (2005) Application of HPLC coupled with DAD, APcI-MS and NMR to the analysis of lutein and zeaxanthin stereoisomers in thermally processed vegetables. *Food Chem* **92**, 755–763.

87. Broekmans WM, Berendschot TT, Klopping-Ketelaars IA, et al. (2002) Macular pigment density in relation to serum and adipose tissue concentrations of lutein and serum concentrations of zeaxanthin. *Am J Clin Nutr* **76**, 595–603.

88. Blaak E (2001) Gender differences in fat metabolism. *Curr Opin Clin Nutr Metab Care* **4**, 499–502.

89. Johnson EJ, Hammond BR, Yeum KJ, et al. (2000) Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. *Am J Clin Nutr* **71**, 1555–1562.

90. Schnohr P, Thomsen OO, Riis HP, et al. (1994) Egg consumption and high-density-lipoprotein cholesterol. *J Intern Med* **235**, 249–251.

91. Herron KL, Lofgren IE, Sharman M, et al. (2004) High intake of cholesterol results in less atherogenic low-density lipoprotein particles in men and women independent of response classification. *Metabolism* **53**, 823–830.

92. Nimalaratne C, Savard P, Gauthier SF, et al. (2015) Bioaccessibility and digestive stability of carotenoids in cooked eggs studied using a dynamic _in vitro_ gastrointestinal model. *J Agric Food Chem* **63**, 2956–2962.